Brief: Theranexus Plans To Expand Its Phase II Pipeline With Third Program
Oct 15 (Reuters) - THERANEXUS SA ALTHX.PA :
* THERANEXUS PLANS TO EXPAND ITS PHASE II PIPELINE WITH A THIRD PROGRAM
* PREPARATION OF A PHASE II PROGRAM FOR THN101 IN PATIENTS WITH NEUROPATHIC PAIN
* PLAN TO LAUNCH A PHASE II CLINICAL TRIAL TO TREAT NEUROPATHIC PAIN WITH THN101 IN FIRST
HALF OF
2019
Source text for Eikon: ID:nACT55520
Further company coverage: ALTHX.PA
(Gdynia Newsroom)
((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Thx Pharma SA
See all newsBrief: Theranexus And BBDF Announce Final And Positive Safety And Efficacy Data In The Phase I/II Trial Testing Batten-1
Brief: Theranexus End-Dec Total Available Funds Stood At EUR 4.9 Mln
Brief: Theranexus Declares Encouraging Prelim Results For Batten Disease Drug
Brief: Theranexus And BBDF Granted Positive Opinion By EMA For Design Of Batten-1 Phase III Trial
Brief: Theranexus And BBDF Win FDA Approval On Endpoints For Phase III Trial To Evaluate Batten-1 In CLN3 Batten Disease